PBH

SEC Filing Summary: Prestige Brands Holdings, Inc. (Form 10-K)

Business Context and Reporting Period

This filing covers the fiscal year ended March 31, 2007. Prestige Brands Holdings, Inc. (Prestige) markets and distributes over-the-counter healthcare, household cleaning, and personal care products globally. The company operates a low-cost model by outsourcing manufacturing and logistics to third-party providers while focusing internal resources on marketing, sales, and product development. Prestige owns 14 major brands, including Chloraseptic, Clear Eyes, Comet, and Cutex, which accounted for approximately 94.1% of net revenues in 2007.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 7.4% to $318.6 million, driven primarily by the acquisitions of the Wartner brand (Sept 2006), Chore Boy, and The Doctor's brands. Excluding acquisitions, organic revenue growth was 0.6%.
• Segment Performance:
  • OTC Healthcare: Revenues up 8.6% to $174.7 million; growth driven by Wartner and The Doctor's, offset by declines in Chloraseptic and Compound W.
  • Household Cleaning: Revenues up 10.4% to $119.0 million; growth driven by Chore Boy and Comet.
  • Personal Care: Revenues declined 10.9% to $24.9 million due to continued declines in Cutex, Denorex, and Prell.
• Margin Compression: Gross margin decreased from 53.0% to 51.9%. This was attributed to inventory obsolescence reserves (specifically $2.6 million related to cough and cold products), higher product costs, and increased shipments to lower-margin international markets.
• Debt Reduction: The company repaid $31.6 million of indebtedness in excess of normal maturities using free cash flow, reducing total debt by approximately $35.2 million.
• Impairment: Unlike 2006, which included $9.3 million in impairment charges for the Personal Care segment, no impairment charges were recorded in 2007.

Guidance, Outlook, and Risks

Outlook and Strategy: Management plans to continue investing in advertising and promotion to drive growth in core brands. The company intends to expand its international business (currently 4.6% of revenue) and pursue strategic acquisitions. New product introductions planned for 2008 include Comet Spray Gel and the Murine Earigate system.

Risks and Contingencies:

• Legal Proceedings: A preliminary injunction was issued in May 2007 prohibiting the sale of the Wartner brand pending arbitration with supplier OraSure Technologies. The company has requested a stay of this injunction, which was granted pending further review. Additionally, a securities class action lawsuit regarding the 2005 IPO remains pending, though claims under the Exchange Act were dismissed in 2006.
• Customer Concentration: Wal-Mart accounted for approximately 24.0% of gross sales in 2007. The top five customers collectively accounted for 43% of sales.
• Supply Chain: The company relies entirely on third-party manufacturers. Approximately 35% of sales are produced by manufacturers with whom the company has no long-term contracts.
• Debt Covenants: The company is subject to restrictive covenants regarding leverage, interest coverage, and fixed charge coverage ratios. Failure to comply could result in debt acceleration.

Investor Verification Checklist

• Wartner Litigation Status: Verify the final resolution of the OraSure Technologies arbitration and the impact of the preliminary injunction on Q4 2007 and FY 2008 revenue.
• Inventory Obsolescence: Monitor future quarters for continued write-downs related to cough and cold products, which impacted margins in 2007.
• Personal Care Segment: Assess the trajectory of the Personal Care segment, which has seen consistent revenue declines and previous goodwill impairments.
• Debt Service Capacity: Review upcoming interest rate environments, as a significant portion of debt is variable-rate, impacting interest expense.
• Acquisition Integration: Evaluate the performance of recently acquired brands (Wartner, Chore Boy, The Doctor's) to ensure they meet projected growth targets.